

1 **SARS-CoV-2 has been circulating in northern Italy since December 2019: evidence from**
2 **environmental monitoring**

3

4

5 Giuseppina La Rosa^{1*}, Pamela Mancini¹, Giusy Bonanno Ferraro¹, Carolina Veneri¹, Marcello
6 Iaconelli¹, Lucia Bonadonna¹, Luca Lucentini¹, Elisabetta Suffredini²

7

8

9 ¹ Department of Environment and Health, Istituto Superiore di Sanità, Rome, Italy

10 ² Department of Food Safety, Nutrition and Veterinary Public Health, Istituto Superiore di Sanità,
11 Rome, Italy

12

13

14

15 **Keywords:** SARS-CoV-2, Coronavirus, COVID-19, sewage, wastewater, surveillance

* **Corresponding author:** Giuseppina La Rosa

Istituto Superiore di Sanità, Department of Environment and Health, Viale Regina Elena 299, 00161, Rome, Italy.
Phone/Fax: 0039-06-49902718. E-mail: giuseppina.larosa@iss.it

16 **ABSTRACT**

17

18 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is responsible for the
19 coronavirus disease COVID-19, a public health emergency worldwide, and Italy is among the
20 world's first and most severely affected countries. The first autochthonous Italian case of COVID-
21 19 was documented on February 21. We investigated the possibility that SARS-CoV-2 emerged in
22 Italy earlier than that date, by analysing 40 composite influent wastewater samples collected - in the
23 framework of other wastewater-based epidemiology projects - between October 2019 and February
24 2020 from five wastewater treatment plants (WTPs) in three cities and regions in northern Italy
25 (Milan/Lombardy, Turin/Piedmont and Bologna/Emilia Romagna). Twenty-four additional samples
26 collected in the same WTPs between September 2018 and June 2019 were included as blank
27 samples. Viral concentration was performed according to the standard World Health Organization
28 procedure for poliovirus sewage surveillance. Molecular analysis was undertaken with both nested
29 RT-PCR and real-time RT-PCR assays. A total of 15 positive samples were confirmed by both
30 methods. Of these, 8 were collected before the first autochthonous Italian case. The earliest dates
31 back to 18 December 2019 in Milan and Turin and 29 January 2020 in Bologna. Samples collected
32 in January and February in the three cities were also positive.

33 Our results demonstrate that SARS-CoV-2 was already circulating in northern Italy at the end of
34 2019. Moreover, it was circulating in different geographic regions simultaneously, which changes
35 our previous understanding of the geographical circulation of the virus in Italy. Our study highlights
36 once again the importance of environmental surveillance as an early warning system, to monitor the
37 levels of virus circulating in the population and identify outbreaks even before cases are notified to
38 the healthcare system.

39 INTRODUCTION

40

41 Coronaviruses (CoVs) belong to the Coronaviridae family and are enveloped, single-stranded RNA
42 viruses, grouped into four main groups: alpha, beta, gamma and delta CoVs. Most human
43 coronaviruses cause mild respiratory infections (CoV 229E, NL63, OC43, and HKU1). Some
44 CoVs, however, are associated with severe symptoms and outbreaks. These are MERS-CoV (the
45 beta coronavirus that causes Middle East Respiratory Syndrome, or MERS), SARS-CoV (the beta
46 coronavirus that causes severe acute respiratory syndrome, or SARS), and the recently discovered
47 SARS-CoV-2 (the novel coronavirus that causes coronavirus disease 2019, or COVID-19).

48 SARS-CoV-2 was discovered in December 2019 in China, and has then spread widely in many
49 countries, to the point that, on 11 March 2020, the World Health Organization (WHO) declared
50 COVID-19 a pandemic. Italy has been among the first, and most severely affected countries in the
51 world - as of 15 June 2020, 237,695 COVID-19 cases were diagnosed, with 33,168 deaths
52 (https://www.epicentro.iss.it/coronavirus/bollettino/Infografica_15giugno%20ITA.pdf). However, it
53 is likely that, in Italy as well as in all other affected countries in the world, the true number of cases
54 has been substantially greater than reported, as mild or asymptomatic infections have often been
55 overlooked.

56 The first SARS-CoV-2 cases reported in Italy were two Chinese tourists who fell ill in January after
57 flying in from Wuhan, where the epidemic began. These patients were immediately put into
58 isolation, and are not believed to have infected anyone else. The first autochthonous patient was
59 diagnosed one month later in Lombardy, on February 21. He was a 38-year-old man, from the town
60 of Codogno, 60 km southeast of Milan. Initially, it was believed that “patient zero” might have been
61 a colleague of his who had recently returned from a business trip to China. This colleague tested
62 negative, however, so the first introduction of the virus into Italy remains unclear.

63 Identifying the first introduction of the virus is of great epidemiological interest. In Italy, and
64 elsewhere, there have been speculations to the effect that COVID-19 had been silently circulating

65 before the first case was identified. Indeed, other countries have been trying to ascertain whether
66 earlier infections had occurred. In France, where the COVID-19 epidemic was believed to have
67 started in late January 2020, a retrospective analysis of a stored respiratory sample from a patient
68 hospitalised in December 2019, demonstrated that the patient was positive for SARS-CoV-2,
69 suggesting that, in France, the epidemic started much earlier than previously thought (Deslandes *et*
70 *al.*, 2020).

71 It is known that gastrointestinal symptoms are seen in patients with COVID-19 (between 16% to
72 33% in most studies), and that approximately 50% of patients with COVID-19 have detectable virus
73 in their stool (Ouali *et al.*, 2020). These patients have been shown to shed the virus in their stools
74 even if asymptomatic or pre-symptomatic (Jiang *et al.*, 2020; Park *et al.*, 2020; Tang *et al.*, 2020).
75 Sewage samples can thus be used to monitor the levels of virus circulating in the population, an
76 approach called wastewater-based epidemiology (WBE). Several studies performed in the
77 Netherlands (Medema *et al.*, 2020), the United States (Wu *et al.*, 2020; Nemudryi *et al.*, 2020),
78 France (Wurtzer *et al.*, 2020), Australia (Ahmed *et al.*, 2020a), Spain (Randazzo *et al.*,
79 2020; Chavarria-Mirò *et al.*, 2020), Japan (Hata *et al.*, 2020), Turkey (Kocamemi *et al.*, 2020), and
80 Israel (Bar-Or *et al.*, 2020) have demonstrated that sewage surveillance can help understand the
81 circulation of SARS-CoV-2 in human populations. In Italy, our group has previously found SARS-
82 CoV-2 in sewage samples collected between the end of February (after the first autochthonous case)
83 and April 2020 (La Rosa *et al.*, 2020). Another Italian study confirmed the occurrence of the virus
84 in sewage samples collected in April (Rimoldi *et al.*, 2020). Thus far, all of the cited studies
85 performed worldwide, have analysed wastewater samples collected during the pandemic, with the
86 exception of the Spanish study of Chavarria-Mirò and co-worker, who also analysed frozen
87 archival samples from 2018 (January-March) and 2019 (January, March, September-December)
88 Chavarria-Mirò *et al.*, 2020). Similarly, in this study we retrospectively searched for genomic traces
89 of SARS-CoV-2 in a collection of sewage samples gathered from WTPs in northern Italy between
90 October 2019 and February 2020, in the framework of different WBE projects on enteric viruses.

91 The samples were analysed to ascertain whether SARS-CoV-2 was circulating in the weeks and
92 months before the virus was believed to have arrived in Italy.

93

94

95

96 **MATERIALS AND METHODS**

97

98 *Sampling and sample preparation*

99 Forty sewage samples were analysed for the study. Samples were collected between 9 October 2019
100 and 28 February 2020 from five WTPs, located in Milan (20 samples from two distinct plants,
101 referred to as A and B), Turin (16 samples from plants C and D), and Bologna (4 samples from
102 plant E). The location and number of inhabitants (expressed as population equivalents) served by
103 these WTPs are summarised in Figure 1. Other 24 wastewater samples, collected from the same
104 WTPs in Milan, Turin and Bologna between 12 September 2018 and 19 June 2019 (i.e. before the
105 emergence of SARS-CoV-2 as a human pathogen), were analysed as ‘blank samples’.

106 Composite samples, representing 24-hour periods, were collected raw, before treatments, stored at -
107 20 °C, and dispatched frozen to Istituto Superiore di Sanità (the Italian National Institute of Health)
108 for analysis. Precautions taken during sample treatment were reported elsewhere (La Rosa et al.,
109 2020). Before sample concentration, a 30 min viral inactivation treatment at 56 °C was undertaken
110 in order to increase the safety of the analytical protocol for both laboratory personnel and the
111 environment. Sample concentration was performed using the two-phase (PEG-dextran) separation
112 method recommended by the WHO Guidelines for environmental surveillance of poliovirus
113 circulation (WHO, 2003), with modifications. Briefly, 250 mL of wastewater sample was
114 centrifuged (30 min at 1200 × g) to separate the pellet. The pellet was kept at 4 °C to be later
115 combined with the concentrated supernatant. The clarified wastewater was neutralized (pH 7.0-7.5),
116 mixed with dextran and polyethylene glycol (19.8 ml of 22% dextran, 143.5 ml 29% PEG 6000,

117 and 17.5 ml 5N NaCl), and after a constant agitation for 30 minutes using a horizontal shaker, the
118 mixture was left to stand overnight at 4 °C in a separation funnel. Viruses, accumulated in the
119 smaller bottom layer and/or at the boundary between the layers (interphase), were then collected
120 drop-wise, and this concentrate was re-joined to the pellet retained after the initial centrifugation. In
121 a previous study by our group on SARS-CoV-2 detection in sewage, the original WHO protocol
122 was modified by omitting the chloroform treatment after collecting the concentrate, to avoid loss of
123 SARS-CoV-2 particles, since lipid-containing viruses are chloroform sensitive (La Rosa et al.,
124 2020). However, RNA obtained from those samples were found to be moderately inhibited (median
125 inhibition 29.1%, range 8.7% - 51.4%). Therefore, after performing comparative extraction
126 experiments with and without chloroform, using field samples and samples spiked with the human
127 Alphacoronavirus HCoV 229E (data not shown), the chloroform purification step was reintroduced
128 to improve the purification of samples before RNA extraction, and obtain a higher detection
129 sensitivity. The concentrated sample was then extracted with 20% (v/v) of chloroform by shaking
130 vigorously for 1 min and centrifugation ($1400 \times g$ for 10 min). The total recovered volume (ranging
131 from 7 to 10 ml) was then recorded, and half of the concentrate was subjected to genome extraction,
132 the remaining being stored at -80 °C.

133 The recovery efficiency of the concentration and extraction procedure was assessed through
134 separate spiking experiments performed in quadruplicate using the Alphacoronavirus HCoV 229E
135 (ATCC VR-740). This was not done on field samples in order to avoid interferences with future
136 virome analyses.

137 Genome extraction was performed using the NucliSENS miniMAG semi-automated extraction
138 system with magnetic silica (bioMerieux, Marcy l'Etoile, France), with the following modifications
139 to the manufacturer's protocol to adapt to large volumes: the quantity of lysis buffer added was the
140 equivalent of twice the volume of the sample, the lysis phase was prolonged to 20 minutes, and 100
141 μ l magnetic silica beads were used per sample. The subsequent washing phases were performed as

142 per manufacturer's instructions. Before molecular tests, extracted RNAs were purified from residual
143 PCR inhibitors using the OneStep PCR Inhibitor Removal Kit (Zymo Research, CA, USA).

144

145 *Nested RT-PCR*

146 RNAs were tested for the presence of SARS-CoV-2 by the nested RT-PCR assays in the ORF1ab
147 region (Table 1) used to detect the first positive sewage samples in Italy (La Rosa et al., 2020).

148 For the assay, first-strand cDNA was synthesized using Super Script IV Reverse Transcriptase
149 (ThermoFisher Scientific) with the reverse primer, according to the manufacturer's instructions.

150 PCR reaction was performed using 2.5 µl of cDNA in a final volume of 25 µl (Kit Platinum
151 SuperFi Green PCR Master Mix, Thermo), using 1 µl of the primer (10 µM). The PCR conditions

152 were as follows: 98 °C for 30 sec; 35 cycles at 98 °C for 10 sec, 54 °C for 10 sec, and 72 °C for 30
153 sec; final extension at 72 °C for 5 min. After the first round of PCR, nested PCR was performed

154 using 2 µl of the first PCR product under the same conditions. A synthetic DNA fragment (Biofab
155 Research, Italy) including the PCR target region was used as positive control. To avoid false-

156 positive results, standard precautions were taken and results were confirmed in two independent
157 experiments.

158 The PCR products were visualised by gel electrophoresis, were purified using a Montage PCRm96
159 Microwell Filter Plate (Millipore, Billerica, MA, USA), and were then sequenced on both strands

160 (BioFab Research, Rome, Italy). Sequences were identified using BLAST analysis
161 (<https://blast.ncbi.nlm.nih.gov/Blast.cgi>). For comparison purposes, all Italian SARS-CoV-2

162 genome sequences available at the time of analysis (12th June 2020; n=134) were retrieved from
163 GISAID (<https://www.gisaid.org/>) and aligned with the study sequences using the MEGA X software

164 (Kumar *et al.*, 2018). Sequences were submitted to NCBI GenBank with the following accession
165 numbers: [*a.n. to be assigned*].

166

167 *Real-time RT-(q)PCR*

168 Analysis by real-time RT-(q)PCR was undertaken with three different protocols (Table 1):

169 a) Two published real-time RT-qPCR assays targeting the E gene of the SARS
170 Betacoronavirus and the RdRp gene of SARS-CoV-2, respectively, as described previously
171 (Corman *et al.*, 2020) with slight modifications. The RT-qPCR mix (25 µl total volume)
172 was prepared using the UltraSense one-step qRT-PCR System (Life Technologies, CA,
173 USA), and 5 µl aliquots of sample RNA were analysed in reactions containing 1× buffer,
174 0.1× ROX reference dye, and 1.25 µl of RNA UltraSense enzyme mix. Primer/probe
175 concentrations were as follows: 400 nM, 400 nM and 200 nM for E_Sarberco_F1,
176 E_Sarberco_R2, and probe E_Sarberco_P1, respectively, and 600 nM, 800 nM, and 250
177 nM for RdRp-SARSr-F2, RdRp-SARSr-R1mod, and probe RdRp-SARSr-P2, respectively.
178 Amplification conditions included reverse transcription for 30 min at 50 °C, inactivation for
179 5 min at 95 °C and 45 cycles of 15 s at 95 °C and 1 min at 58 °C. For standard curve
180 construction, the two targeted regions were synthesized and quantified by Eurofins
181 Genomics (Germany). Tenfold dilutions were used for standard curve construction.

182 b) A newly developed real-time RT-(q)PCR designed using the Primer3 software
183 (<http://primer3.ut.ee/>) targeting the ORF1ab region (nsp14; 3'-to-5' exonuclease) of the
184 SARS-CoV-2 genome (positions 18600-18699 of GenBank accession number
185 NC_045512). Following optimization, the RT-qPCR mix (25 µl total volume) was prepared
186 using the AgPath-ID One-Step RT-PCR (Life Technologies), and 5 µl of sample RNA were
187 analysed in reactions containing 1× RT-PCR buffer, 1 µl of RT-PCR enzyme mix, 1.67 µl
188 of detection enhancer, and 500 nM, 900 nM, and 250 nM of primer 2297-CoV-2-F, primer
189 2298-CoV-2-R, and probe 2299-CoV-2-P, respectively. Amplification conditions were:
190 reverse transcription for 30 min at 50 °C, inactivation for 5 min at 95 °C and 45 cycles of
191 15 s at 95 °C and 30 s at 60 °C. For standard curve construction, the targeted region was
192 synthesized and purified by BioFab Research (Italy), and was quantified by fluorometric
193 measure (Qubit, Thermo Scientific). Tenfold dilutions were used for standard curve

194 construction. In vitro synthesized RNA containing the target region was used as an external
195 amplification control to check for PCR inhibition.

196 Reactions for quantitative analysis were performed in duplicate. Amplifications were considered
197 acceptable if inhibition was $\leq 50\%$ and if standard curves displayed a slope between -3.1 and -3.6
198 and a $R^2 \geq 0.98$. All amplifications were conducted on a Quant Studio 12K Flex instrument (Thermo
199 Scientific). Molecular biology grade water served as the no-template control; two negative controls
200 were included in each run to check for reagent contamination and for environmental contamination,
201 respectively.

202 Since analysis on environmental matrices may occasionally display high fluorescence background
203 or non-exponential amplification (fluorescence ‘drift’) during amplification, a conservative
204 approach was applied for data analysis. All amplification plots were visually checked for
205 exponential amplification, the threshold was manually set at the midpoint of the exponential phase,
206 and a C_q cut-off value of 40 was applied to all results.

207

208 *Specificity and sensitivity of nested RT-PCR and real-time RT-(q)PCR*

209 Our in-house nested RT-PCR was evaluated for specificity using the European Virus Archive –
210 EVA GLOBAL (EVAg) panel, kindly provided by the Erasmus University Medical Center
211 (Rotterdam, The Netherlands), and consisting of RNAs from different Alfa- and Beta-
212 coronaviruses (HCoV-NL63, HCoV-229E, HCoV-OC43, MERS-CoV, SARS-CoV and SARS-
213 CoV-2). Moreover, all amplicons obtained by nested PCR were sequenced for confirmation and
214 compared with those available in GeneBank and in GISAID (<https://www.gisaid.org/>). The real-time
215 RT-(q)PCR was evaluated for specificity using the GLOBA (EVAg) panel and, in addition, in order
216 to exclude possible aspecific signals, specificity was also tested against a panel of nucleic acids
217 from viruses ($n=32$) and bacteria ($n=15$), as detailed in Supplementary Material. Further to this, to
218 assess specificity of the test on samples representative of the natural microbiota of sewage, 24
219 ‘blank’ sewage samples (see above) were tested by both molecular methods.

220 As for sensitivity, in the absence of certified reference material for quantitative assays, SARS-CoV-
221 2 RNA provided in the EVAg panel (quantified $\sim 3 \times 10^4$ genome copies (g.c.)/ μ l using our in-house
222 real-time RT-(q)PCR) was used to prepare a serial dilution to assess the sensitivity of the method's
223 on pure samples of target RNA. The same dilutions were then used to spike nucleic acids extracted
224 from SARS-CoV-2 negative sewage concentrates, in order to evaluate the method's performance in
225 wastewater samples. The dilutions were tested by nested RT-PCR (one replicate) to determine the
226 lower detectable concentration of the method, and were analysed in quadruplicate to calculate the
227 limit of detection (LOD₅₀) and the limit of quantification (LOQ) of the real-time RT-(q)PCR assay.
228 LOD₅₀ was calculated according to Wilrich and Wilrich (2009), using the tools available in
229 <https://www.wiwiss.fu-berlin.de/fachbereich/vwl/iso/ehemalige/wilrich/index.html>). LOQ was
230 calculated as the last dilution level at which the relative repeatability standard deviation (RSDr) of
231 the measurements was below 25 % (Hougs *et al.*, 2017).

232

233

234 **RESULTS**

235

236 Our nested RT-PCR was able to detect the presence of SARS-CoV-2 RNA in spiked sewage
237 samples in a concentration of 3.71 g.c./ μ l. On pure samples of target RNA, the real-time RT-
238 (q)PCR yielded a LOD₅₀ of 0.41 g.c./ μ l (2.05 g.c./reaction) and a LOQ of 3.71 g.c./ μ l; in sewage
239 samples, LOD₅₀ and LOQ were 1.46 g.c./ μ l RNA (7.30 g.c./reaction) and 7.35 g.c./ μ l, respectively.

240 As regards the specificity of the two assays, amplification was obtained only in reactions containing
241 SARS-CoV-2 RNA (EVAg Coronavirus panel), and no aspecific amplification was detected for the
242 other human coronaviruses, for the RNA/DNA panel of enteric viruses and bacteria, or for the 24
243 'blank' sewage samples collected between September 2018 and June 2019.

244 The recovery efficiency of the concentration and extraction procedure, evaluated with seeded
245 experiments performed in quadruplicate, using the Alphacoronavirus HCoV-229E (ATCC VR-740)

246 showed an average recovery of $2.04 \pm 0.70\%$. Sample inhibition, assessed by real-time RT-(q)PCR,
247 ranged from null to 49.0%, with a median value of 3.2%.

248 With regard to the 40 sewage samples collected between October 2019 and February 2020 from the
249 WTPs in Milan, Turin and Bologna, SARS-CoV-2 RNA was detected by nested RT-PCR in 18
250 samples (amplicon sequences confirmed as SARS-CoV-2 by blast analysis) and in 26 samples by
251 the newly developed real-time RT-(q)PCR (Table 2), with an overall agreement between the two
252 assays of 65.0% (26/40 paired results). In 15 samples, SARS-CoV-2 RNA was detected by both
253 methods. Only these samples, that tested positive by both nested and real-time PCR, were
254 considered as confirmed positive samples. None of the samples tested positive using the previously
255 published SARS-CoV-2 RdRp and Sarbeco E gene protocols.

256 Of the 15 positive samples, 8 were taken earlier than February 21, i.e. before the first autochthonous
257 Italian case was reported. Specifically, the first SARS-CoV-2 positive sewage samples were
258 collected as early as and 18 December 2019 in Milan and Turin and 29 January 2020 in Bologna. In
259 all three cities, the virus was also detected in the samples collected subsequently, in January and
260 February, with only one exception - the February sample from Bologna. Here, however, the
261 negative real-time RT-(q)PCR result may have been affected by the slightly higher-than-usual
262 inhibition in this amplification (16.3%). Virus concentration in the positive samples (Table 2 and
263 Figure 2) ranged from <LOD to 5.6×10^4 g.c./L, and most of the samples (23/26) were below the
264 analytical LOQ (5.9×10^3 g.c./L). The highest concentration was recorded in a sample collected in
265 Turin, in February 2020 (plant C, 5.6×10^4 g.c./L).

266

267

268

269 **DISCUSSION**

270 The COVID-19 pandemic first broke out in December 2019 in Wuhan, China, and then rapidly
271 spread worldwide. As of 22 June 2020, 9 million cases of COVID-19 have been registered, and
272 over 470 thousand deaths have been reported (<https://www.worldometers.info/coronavirus/>).

273 Italy is one of the first and most severely affected countries in Europe, with a high number of
274 documented cases and deaths. The first documented cases (30th January 2020) were two Chinese
275 tourists who fell ill in Italy in late January after flying in from Wuhan, where the epidemic began.

276 The first autochthonous case of infection was recorded in Italy on 21 February 2020. A sustained
277 local transmission has been documented, so that by 15 June 2020, 237.695 COVID-19 cases had
278 been diagnosed, with 33.168 deaths

279 (https://www.epicentro.iss.it/coronavirus/bollettino/Infografica_15giugno%20ITA.pdf). As far as
280 we know, COVID-19 first affected Lombardy and Veneto and, later on, all the other regions of

281 Italy. The vast majority of cases were reported in Northern Italy. Phylogenetic analyses on SARS-
282 CoV-2 sequences conducted at the beginning of the epidemic, cluster Italian sequences far from the
283 first two Chinese tourists' strains, and suggest that there may have been multiple introductions of

284 the virus into Italy (Bartolini *et al.*, 2020; Giovanetti *et al.*, 2020; Stefanelli *et al.*, 2020), followed
285 by autochthonous transmission. A genomic characterisation and phylogenetic analysis performed on
286 complete SARS-CoV-2 genomes isolated from patients involved in the first outbreak of COVID-19

287 in Lombardy, suggested that SARS-CoV-2 entered Northern Italy weeks before the first reported
288 case of infection (Zehender *et al.*, 2020).

289 To test this hypothesis, we analysed sewage samples collected between October 2019 and February
290 2020 in Northern Italy in the framework of WBE projects on enteric viruses and stored in the
291 archive of the Department of Environment and Health at the Italian National Institute of Health. In a

292 previous study, we demonstrated the presence of SARS-CoV-2 in untreated wastewaters in Italy by
293 analysing samples collected during the early stages of the epidemic (February to April 2020) (La
294 Rosa *et al.*, 2020), and other studies around the world have demonstrated that SARS-CoV-2
295 surveillance in sewage may be considered a sensitive tool to monitor the spread of the virus in the

296 population (Ahmed *et al.*, 2020a;Hata *et al.*, 2020;Medema *et al.*, 2020;Randazzo *et al.*, 2020;Wu *et*
297 *al.*, 2020;Wurtzer *et al.*, 2020; Kocamemi *et al.*, 2020; Bar-Or *et al.*, 2020)).

298 In this study, the analysis of archival samples shows that SARS-CoV-2 was already circulating in
299 Italy, shed by symptomatic, asymptomatic or paucisymptomatic people, many weeks before the first
300 documented autochthonous case, reported on February 21th. Specifically, viral RNA first occurred
301 in sewage samples collected on December 18th, in Milan (Lombardy) and Turin (Piedmont).
302 Therefore, after mid-December 2019, SARS-CoV-2 had already been circulating in major urban
303 centres surrounding the area (Codogno, in the province of Lodi) where the first case of COVID-19
304 was reported in February 2020. Significantly, all of these regions documented COVID-19 cases
305 starting from 25 February (Protezione Civile, 2020).

306 A considerable body of evidence supports the hypothesis that SARS-CoV-2 had been circulating in
307 Italy, as well as in other countries, as early as the end of 2019. Indeed, the fact that the virus had
308 been circulating in Europe in late December 2019 has already been demonstrated by a French study
309 (Deslandes *et al.*, 2020) that retrospectively analysed samples taken from intensive care patients
310 with influenza-like symptoms in Paris, and found one SARS-CoV-2 positive respiratory sample in a
311 French resident who had not visited China and who had been hospitalised on December 27.
312 Considering the incubation period of COVID-19 - 6.4 days on average (Wang *et al.*, 2020) - as
313 well as evidence showing that viral shedding may occur in asymptomatic patients (Jiang *et al.*,
314 2020; Park *et al.*, 2020; Tang *et al.*, 2020), it is conceivable that the virus was circulating and being
315 released into the sewage in the Paris area roughly at the same time as in northern Italy, as indicated
316 by our positive sewage samples.

317 Further evidence that SARS-CoV-2 had been spreading far earlier than previously thought came
318 from the United States, where the California health authorities announced that, according to autopsy
319 results, the first death from COVID-19 had to be backdated to 6 February 2020, approximately
320 three weeks before the previously ascertained first US death from the virus
321 (<https://edition.cnn.com/2020/04/22/us/california-deaths-earliest-in-us/index.html>). In China, where

322 the first case of a novel pneumonia in Wuhan city, Hubei province, was reported in late December
323 2019, a retrospective analysis identified a patient with symptom onset as early as 1 December
324 (WHO, 2020;Zhang & Holmes, 2020). These indications support scientists' suspicions that SARS-
325 CoV-2 had been circulating undetected for a relatively long period before the first wave of the
326 epidemic hit.

327 Additional indications pointing to SARS-CoV-2 circulation before the identification of clinical
328 cases come from WBE studies. In Spain, SARS-CoV-2 was detected in Barcelona wastewaters 41
329 days (January 15) before the declaration of the first COVID-19 case (February 25), clearly
330 illustrating the ability of wastewater surveillance to anticipate the appearance of cases in the
331 population (Chavarria-Mirò *et al.*, 2020). Another Spanish study in the region of Murcia detected
332 SARS-CoV-2 RNA in wastewater before the first COVID-19 cases were declared by the local
333 authorities (Randazzo *et al.*, 2020). A similar study conducted in France showed SARS-CoV-2 viral
334 genome in raw sewage before the exponential phase of the epidemic, suggesting that the
335 contamination of wastewaters may occur before any significant appearance of clinical cases
336 (Wurtzer *et al.*, 2020).

337 The hypothesis of SARS-CoV-2 circulation before the identification of the first clinical cases is
338 supported by other epidemiological approaches as well: a seroprevalence study, conducted on
339 healthy blood donors in the province of Milan during the COVID-19 epidemic showed that, at the
340 beginning of the outbreak (24 February), 2.0% of donors displayed IgG for SARS-CoV-2 (Valenti,
341 *et al.*, 2020), suggesting that the virus had already been circulating in the population of Milan
342 before the presumed beginning of the outbreak.

343 Evolutionary sequence analyses lend credibility to the scenario of an introduction of SARS-CoV-2
344 into the human population in the fourth quarter of 2019 (Duchene *et al.*, 2020; Giovanetti *et al.*,
345 2020; Hill & Rambaut, 2020; Li *et al.*, 2020;Lu *et al.*, 2020; Volz *et al.*, 2020). Recently, van Dorp
346 and co-workers analysed the genomic diversity of SARS-CoV-2 in the global population since the
347 beginning of the COVID-19 pandemic by comparing 7666 SARS-CoV-2 genomes covering a vast

348 geographical area (van Dorp *et al.*, 2020). Results showed that all sequences shared a common
349 ancestor towards the end of 2019 (6 October 2019 - 11 December 2019), indicating this as the
350 period when SARS-CoV-2 jumped into the human population, and that the virus may have been
351 transmitted between human hosts for quite some time before it was identified.

352 Other elements in support of our findings may be found in the press. According to a Reuters report
353 from March 26, a “significant” increase in the number of people hospitalised with pneumonia and
354 flu-like symptoms in the areas of Milan and Lodi had been documented between October and
355 December 2019 (<https://it.reuters.com/article/idUSKBN21D2IG>). Clearly, since the virus was still
356 unknown on those dates, the disease would likely have been diagnosed as flu-related. In Turin,
357 between December 2019 and February 2020, the number of patients with a chest CT-scans
358 consistent with COVID-19 pneumonia was four times higher than the number of retrospectively
359 examined CT-scans between December 2018 and February 2019
360 ([https://torino.repubblica.it/cronaca/2020/06/19/news/boom_di_polmoniti_invernali_gia_a_dicembr
361 e_il_coronavirus_circolava_a_torino-259645769/](https://torino.repubblica.it/cronaca/2020/06/19/news/boom_di_polmoniti_invernali_gia_a_dicembr_e_il_coronavirus_circolava_a_torino-259645769/)). In the region of Liguria, a study conducted by
362 the regional health services (ALISA) showed that samples from blood donors collected in early
363 January revealed the presence of anti-SARS-CoV-2 IgG, thus pointing to an infection in December
364 ([https://www.news1.news/en/2020/05/the-coronavirus-arrived-in-liguria-long-before-codognos-
365 patient-zero-2.html](https://www.news1.news/en/2020/05/the-coronavirus-arrived-in-liguria-long-before-codognos-patient-zero-2.html)).

366 In agreement with the above data, our study indicates that SARS-CoV-2 was present in Italy before
367 the first imported cases were reported in late January 2020. Since faecal viral shedding occurs in
368 both symptomatic and asymptomatic patients, the question remains whether the traces of SARS-
369 CoV-2 RNA that we found in the sewage of Milan, Turin and Bologna reflected the presence of a
370 significant number of asymptomatic carriers, or of symptomatic patients diagnosed as cases of
371 influenza.

372 In the present study, several analytical issues had to be addressed. The method used for sample
373 concentration is a modified protocol for the surveillance of poliovirus in sewage. Different volumes

374 and concentration methods are being applied in the various studies assessing the occurrence of
375 SARS-CoV-2: adsorption-extraction with different pre-treatment options, centrifugal concentration
376 device methods, polyethylene glycol concentration, and ultrafiltration (Ahmed et al., 2020b). The
377 concentration method used in this study, based on the two-phase (PEG-dextran) separation method,
378 was selected despite the fact that recovery efficiencies seem to be lower than those obtained by
379 other methods (Ahmed et al., 2020b). It is, however, recommended by the WHO Guidelines for
380 environmental surveillance and is the standard for enteric virus sewage surveillance worldwide
381 (WHO, 2003). This means that a number of laboratories already have both the know-how and the
382 equipment necessary to perform it. Moreover, samples that are routinely collected and concentrated
383 for poliovirus surveillance could be shared and used for SARS-CoV-2 surveillance as well, thus
384 optimising economic and personnel resources.

385 As for the method used for SARS-CoV-2 detection and quantification, the nested RT-PCR targeting
386 the ORF1ab region, previously published for the first detection of SARS-CoV-2 in wastewater in
387 Italy (La Rosa *et al.*, 2020), was tested in this study for specificity against a panel of human
388 coronavirus RNAs and ‘blank’ samples. Moreover, as a routine procedure for all conventional
389 PCRs, the identity of all amplified fragments was confirmed by sequencing. The newly designed
390 real-time RT-(q)PCR assay described in this study was shown to be specific for SARS-CoV-2 by
391 testing against the human coronavirus panel, nucleic acids from relevant viruses and bacteria and
392 ‘blank’ samples. While cross-reactivity with untested microorganisms or with uncharacterised
393 viruses displaying sequences closely matching the target region may not be excluded in principle,
394 the absence of any amplification in ‘blank’ samples seems to confirm the specificity of the reaction.
395 Further tests on a larger variety of reference strains and complex matrices, however, should be
396 performed for full validation of this method. The sensitivity of the real-time RT-(q)PCR assay
397 targeting nsp14 was also assessed, using spiked nucleic acids simulating a wastewater matrix
398 contaminated with SARS-CoV-2. In preliminary tests on these samples this in-house assay proved
399 to be more sensitive than the RdRp test (Corman *et al.*, 2020) recommended for the screening

400 clinical samples (data not shown). Indeed, sewage is a very complex matrix, and assays developed
401 for clinical samples are not always suitable for use on environmental samples. It should be noted
402 that, in the absence of an internationally recognised standard for SARS-CoV-2 quantification (as
403 available for other human viruses), a robust assessment of the sensitivity and accuracy of real-time
404 RT-(q)PCR assays cannot be performed, as quantitative results are prone to error depending on both
405 the amplification efficiency of the reactions and the trueness of the reference values attributed to
406 standard curves. Indeed, several studies performing the simultaneous quantification of samples by
407 multiple targets or protocols, as required for example in the CDC protocol testing for N1 and N2
408 (CDC, 2020), showed significant variability in the values resulting from the different targets
409 (Nemudryi *et al.*, 2020, Randazzo *et al.*, 2020, Wu *et al.*, 2020, Peccia *et al.*, 2020, Hata *et al.*,
410 2020), at times displaying differences of up to 3 log in the quantities estimated through different
411 protocols (Chavarria-Miro *et al.*, 2020). Further method harmonization, the development of certified
412 reference materials and a robust characterisation of the method's performance (including estimation
413 of LOD, LOQ and measurement uncertainty) are required for a reliable use of real-time RT-(q)PCR
414 in SARS-CoV-2 quantification in sewage, particularly in view of the use of these data for WBE, as
415 done in some recent studies (Ahmed *et al.*, 2020a).

416 In this study on samples from the pre-epidemic period (October 2019 to February 2020), virus
417 concentrations in the tested wastewater samples ranged from undetectable to 5.6×10^4 g.c./L, with
418 most results in the order of 10^2 – 10^3 g.c./L. These results are consistent with the concentrations
419 obtained by other authors who tested samples collected at a later stage of the pandemic (mid-
420 January through May 2020) in different countries, finding values ranging from 10^2 to 10^6 g.c./L
421 (Ahmed *et al.*, 2020a; Chavarria-Mirò *et al.*, 2020; Randazzo *et al.*, 2020; Wu *et al.*, 2020; Wurtzer
422 *et al.*, 2020; Kocameni *et al.*, 2020). In some of these studies, an upward trend in viral
423 concentrations was observed over the course of the epidemic. Wurtzer *et al.* (2020) showed SARS-
424 CoV-2 concentrations in Paris wastewaters to increase from 10^4 – 10^5 g.c./L at the beginning of the
425 epidemic to 10^6 – 10^7 g.c./L after its peak. An increase in line with the trend in the local population

426 was also observed in a New Haven (Connecticut, US) study, where concentrations rose from 10^6 to
427 10^8 g.c./L (Peccia *et al.*, 2020) and in Barcelona (Spain), where virus amounts went from less than
428 10^2 g.c./L at the beginning of the monitoring to approximately 10^4 g.c./L, and then progressively
429 declined again toward 10^2 g.c./L (Chavarria-Miró *et al.*, 2020). In other studies, perhaps due to
430 shorter periods of observation, an almost constant concentration of SARS-CoV-2 in tested samples
431 was reported following its first detection (Randazzo *et al.*, 2020; Hata *et al.*, 2020). While the high
432 number of results below the LOQ obtained in our study did not allow for an accurate trend analysis,
433 quantitative data in samples from Milan showed that, following the first occurrence of the virus, an
434 almost constant concentration was reached in sewage samples, while in Turin, the different plants
435 sampled, – serving different districts of the metropolitan area – displayed different tendencies, with
436 a more evident increase in concentrations in plant C. Further studies on samples collected from
437 February 2020 are required to assess the trends in viral concentrations as the epidemic unfolded in
438 the different cities. Moreover, possible differences between WTPs and the areas they serve should
439 be taken into account in future surveillance studies.

440 In conclusion, our study on archival samples collected before the first autochthonous case was
441 detected confirm that SARS-COV-2 was already circulating in Italy after mid-December 2019, as
442 demonstrated in France by retrospective analysis of stored respiratory samples (Deslandes *et al.*,
443 2020). This study also demonstrates the potential of environmental surveillance as an early warning
444 system capable of alerting public health authorities to the presence of an outbreak in a specific
445 population. The activation of national WBE networks for the monitoring of SARS-CoV-2 could
446 contribute to the early detection of a possible second wave of infection, so as to quickly coordinate
447 and implement mitigation interventions, and could establish a surveillance system ready to operate
448 in case of future epidemic events.

449

450 **Acknowledgments**

451 This publication was supported by the European Virus Archive Global (EVA-GLOBAL) project,
452 which provided the Coronavirus RNA panel for the assessment of our in-house PCR. The EVA-
453 GLOBAL project, in turn, received funding from the European Union's Horizon 2020 research and
454 innovation programme under grant agreement No 871029.

455 We also wish to acknowledge Prof. Annalaura Carducci of the University of Pisa for kindly
456 providing the HuCoV 229E (ATCC VR-740) strain and Dr. Loredana Cozzi (Istituto Superiore di
457 Sanità, Department of Food Safety, Nutrition and Veterinary public health) for virus replication.

458 We thank the personnel of the integrated water service for providing wastewater samples.

459 **Table 1: Primers and amplification protocols used in the study**

460

Target	Region	Primer Name	Nucleotide sequence	Orienta tion	Usage	Amplicon size (bp)	Reference
SARS-CoV-2	ORF1ab (nsp14)	2274 - CO-FW1	GTGCTAAACCACCGCCTG	+	First PCR	368	La Rosa, 2020
		2275 - CO-REV1	CAGATCATGGTTGCTTTGTAGGT	-			
		2276 - CO-FW2	CGCCTGGAGATCAATTTAAACAC	+	Nested PCR	332	
		2277 - CO-REV2	ACCTGTAAAACCCCATTTGTTGA	-			
SARS-CoV-2	ORF1ab (nsp14)	2297-CoV-2-F	ACATGGCTTTGAGTTGACATCT	+	Real-time RT-qPCR	-	This study
		2298-CoV-2-R	AGCAGTGGAAAAGCATGTGG	-			
		2299-CoV-2-P	FAM-CATAGACAACAGGTGCGCTC-MGBEQ				
SARS Betacoronavirus	E gene	E_Sarbeco_F1	ACAGGTACGTTAATAGTTAATAGCGT	+	Real-time RT-qPCR	-	Corman et al., 2020
		E_Sarbeco_R2	ATATTGCAGCAGTACGCACACA	-			
		E_Sarbeco_P1	FAM-ACACTAGCCATCCTTACTGCGCTTCG-BHQ1				
SARS-CoV-2	RdRp	RdRp_SARSr-F2	GTGARATGGTCATGTGTGGCGG	+	Real-time RT-qPCR	-	Corman et al., 2020 This study
		RdRp_SARSr-R1mod	CARATGTTAAAAACACTATTAGCATA	-			
		RdRp_SARSr-P2	FAM-CAGGTGGAACCTCATCAGGAGATGC- BHQ1				

461

462 FAM: 6-Carboxyfluorescein; MGBEQ: Minor Groove Binder Eclipse Quencher; BHQ1: Black Hole Quencher-1

463 Primer RdRp_SARSr-R1 was modified by substituting the degenerate base in position 12, as suggested by Vogel et al. (2020) to increase sensitivity.

464
465
466


Table 2: SARS-CoV-2 detection in sewage samples, October 2019 – February 2020

Sample ID	Origin	Date of sampling	WTP	Nested RT-PCR	Real-time RT-(q)PCR (c.g./L)
3285	Milan	24/10/2019	A	-	-
3287	Milan	25/11/2019	A	-	-
3289	Milan	18/12/2019	A	+	4.1×10^3
3290	Milan	18/12/2019	A2	-	8.7×10^2
3238	Milan	20/12/2019	B	+	1.2×10^3
3291	Milan	29/01/2020	A	+	2.3×10^3
3292	Milan	29/01/2020	A2	-	2.2×10^3
3244	Milan	03/02/2020	B	-	6.1×10^2
3231	Milan	12/02/2020	A	-	1.6×10^3
3239	Milan	12/02/2020	B	-	2.8×10^3
3232	Milan	19/02/2020	A	+	-
3240	Milan	19/02/2020	B	-	2.6×10^3
3241	Milan	23/02/2020	B	+	1.5×10^3
3233 *	Milan	24/02/2020	A	+	9.2×10^2
3230	Milan	25/02/2020	A	+	4.8×10^2
3237	Milan	25/02/2020	A2	-	1.4×10^3
3234	Milan	26/02/2020	A	+	3.7×10^3
3242	Milan	26/02/2020	B	-	1.7×10^3
3235	Milan	28/02/2020	A	-	-
3243 *	Milan	28/02/2020	B	+	1.3×10^3
3144	Turin	09/10/2019	C	-	-
3145	Turin	09/10/2019	C	-	-
3321	Turin	06/11/2019	C	-	-
3323	Turin	06/11/2019	D	-	-
3325	Turin	20/11/2019	C	-	-
3329	Turin	04/12/2019	C	-	-
3331	Turin	04/12/2019	D	-	-
3333	Turin	18/12/2019	C	+	-
3335	Turin	18/12/2019	D	+	1.2×10^3
3337	Turin	14/01/2020	C	+	7.4×10^2
3339	Turin	15/01/2020	D	+	1.2×10^3
3341	Turin	28/01/2020	D	+	5.6×10^2
3343	Turin	29/01/2020	C	-	6.0×10^2
3345	Turin	11/02/2020	D	-	4.7×10^2
3347	Turin	25/02/2020	D	+	2.9×10^2
3349	Turin	26/02/2020	C	+	5.6×10^4
3374	Bologna	21/11/2019	E	-	-
3375	Bologna	10/12/2019	E	-	2.9×10^4
3376	Bologna	29/01/2020	E	+	3.3×10^4
3377	Bologna	19/02/2020	E	+	-

467 Highlighted in bold are the first occurrences of SARS-CoV-2 in each of the urban areas included in
468 the study. 'A2' represents a second branch of the 'A' wastewater treatment plant. Samples below
469 5.9×10^3 g.c./L (LOQ) should be considered as estimated counts.


470 * Samples detected as positive in a previous study (La Rosa *et al.*, 2020) and confirmed as such by
471 repeating both the extraction and the molecular analysis.

472 **Figure 1: Location and number of inhabitants served by the WTPs included in the study**



473
474 Numbers in correspondence of the WTP code represent the inhabitants served by each plant

475 **Figure 2: Trend of SARS-CoV-2 detection in Milan, Turin and Bologna during the observed**
476 **period**



477
478 All quantitative values obtained by real time RT-(q)PCR are reported, irrespectively of confirmation of positive results
479 by nested RT-PCR

480

481

482

483

484

References

485

486 Ahmed, W., Angel, N., Edson, J., Bibby, K., Bivins, A., O'Brien, J. W., Choi, P. M., Kitajima, M.,
487 Simpson, S. L., Li, J., Tschärke, B., Verhagen, R., Smith, W. J. M., Zaugg, J., Dierens, L.,
488 Hugenholtz, P., Thomas, K. V., Mueller, J. F., 2020a. First confirmed detection of SARS-
489 CoV-2 in untreated wastewater in Australia: A proof of concept for the wastewater
490 surveillance of COVID-19 in the community. *The Science of the Total Environment* 728,
491 138764.

492 Ahmed, W., Bertsch, P. M., Bivins, A., Bibby, K., Farkas, K., Gathercole, A., Haramoto, E.,
493 Gyawali, P., Korajkic, A., McMinn, B. R., Mueller, J. F., Simpson, S. L., Smith, W.,
494 Symonds, E. M., Thomas, K. V., Verhagen, R., Kitajima, M., 2020. Comparison of virus
495 concentration methods for the RT-qPCR-based recovery of murine hepatitis virus, a
496 surrogate for SARS-CoV-2 from untreated wastewater. *The Science of the Total*
497 *Environment* 739, 139960. <https://doi.org/10.1016/j.scitotenv.2020.139960>

498 Bar-Or, I., Yaniv, K., Shagan, M., Ozer, E., Erster, O., Mendelson, E., Mannasse, B., Shirazi, R.,
499 Kramarsky-Winter, E., Nir, O., Abu-Ali, H., Ronen, Z., Rinott, E., Lewis, Y.E., Friedler, E.,
500 Bitkover, E., Paitan, Y., Berchenko, Y., Kushmaro, A., 2020. Regressing SARS-CoV-2
501 sewage measurements onto COVID-19 burden in the population: a proof-of-concept for
502 quantitative environmental surveillance. *medRxiv* preprint.
503 <https://doi.org/10.1101/2020.04.26.20073569>

504 Bartolini, B., Rueca, M., Gruber, C. E. M., Messina, F., Carletti, F., Giombini, E., Lalle, E., Bordi,
505 L., Matusali, G., Colavita, F., Castilletti, C., Vairo, F., Ippolito, G., Capobianchi, M. R., Di,
506 C. A., 2020. SARS-CoV-2 Phylogenetic Analysis, Lazio Region, Italy, February-March
507 2020. *Emerging Infectious Diseases* 26.

508 CDC, 2020. CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel.
509 <https://www.fda.gov/media/134922/download>

510 Chavarria-Mirò, G., Anfruns-Estrada, E., Guix, S., Paraira, M., Galofrè, B., SÁnchez, G., Pintò,
511 R., Bosch, A., 2020. Sentinel surveillance of SARS-CoV-2 in wastewater anticipates the
512 occurrence of COVID-19 cases. *medRxiv* preprint.
513 <https://doi.org/10.1101/2020.06.13.20129627>

514 Corman, V. M., Landt, O., Kaiser, M., Molenkamp, R., Meijer, A., Chu, D. K., Bleicker, T.,
515 BrÄ¼nink, S., Schneider, J., Schmidt, M. L., Mulders, D. G., Haagmans, B. L., van, d., V,
516 van den Brink, S., Wijsman, L., Goderski, G., Romette, J. L., Ellis, J., Zambon, M., Peiris,
517 M., Goossens, H., Reusken, C., Koopmans, M. P., Drosten, C., 2020. Detection of 2019
518 novel coronavirus (2019-nCoV) by real-time RT-PCR. *Eurosurveillance* 25.

519 Deslandes, A., Berti, V., Tandjaoui-Lambotte, Y., Alloui, C., Carbonnelle, E., Zahar, J. R., Brichtler,
520 S., Cohen, Y., 2020. SARS-CoV-2 was already spreading in France in late December 2019.
521 *International Journal of Antimicrobial Agents* 55, 106006.

522 Duchene, S., Featherstone, L., Haritopoulos-Sinanidou, L., 2020. Temporal signal and the
523 evolutionary rate of 2019 n-CoV using 47 genomes collected by Feb 01 2020.

- 524 Giovanetti, M., Angeletti, S., Benvenuto, D., Ciccozzi, M., 2020. A doubt of multiple introduction
525 of SARS-CoV-2 in Italy: A preliminary overview. *Journal of Medical Virology*, 1-3
- 526 Hata, A., Honda, R., Hara-Yamamura, H., Meuchi, Y., 2020. Detection of SARS-CoV-2 in
527 wastewater in Japan by multiple molecular assays-implication for wastewater-based
528 epidemiology (WBE). *medRxiv preprint*. doi: <https://doi.org/10.1101/2020.06.09.20126417>
- 529 Hill, V. & Rambaut, A. (2020). Phylodynamic analysis of SARS-CoV-2 | Update 2020-03-06 .
- 530 Hougs, L., Gatto, F., Goerlich, O., Grohmann, L., Lieske, K., Mazzara, M., Narendja, F., Ovesna,
531 J., Papazova, N., Scholtens, I., Žel, J., 2017. Verification of analytical methods for GMO
532 testing when implementing interlaboratory validated methods. EUR 29015 EN, Publication
533 Office of the European Union, Luxembourg, 2017, ISBN 978-92-79-77310-5,
534 doi:10.2760/645114, JRC 109940.
- 535 Jiang, X., Luo, M., Zou, Z., Wang, X., Chen, C. & Qiu, J., 2020. Asymptomatic SARS-CoV-2
536 infected case with viral detection positive in stool but negative in nasopharyngeal samples lasts for
537 42 days. *Journal of Medical Virology*. doi:10.1002/jmv.25941.
- 538 Kocamemi, B. A., Kurtb, H., Hacıoğlu S., Yaralı C., Saatci, A.M., Pakdemirli, B., 2020. First
539 Data-Set on SARS-CoV-2 Detection for Istanbul Wastewaters in Turkey. *medRxiv preprint*.
540 <https://doi.org/10.1101/2020.05.03.20089417>doi.
- 541 Kumar, S., Stecher, G., Li, M., Knyaz, C., Tamura, K., 2018. MEGA X: Molecular Evolutionary
542 Genetics Analysis across Computing Platforms. *Molecular Biology and Evolution*. 35:1547–
543 1549.
- 544 La Rosa, G., Iaconelli, M., Mancini, P., Bonanno Ferraro, G., Veneri, C., Bonadonna, L., Lucentini,
545 L., Suffredini, E., 2020. First detection of SARS-CoV-2 in untreated wastewaters in Italy.
546 *The Science of the Total Environment* 736, 139652.
- 547 Li, X., Wang, W., Zhao, X., Zai, J., Zhao, Q., Li, Y. & Chaillon, A., 2020. Transmission dynamics
548 and evolutionary history of 2019-nCoV. *Journal of Medical Virology* 92, 501-511.
- 549 Lu, J., du, P. L., Liu, Z., Hill, V., Kang, M., Lin, H., Sun, J., Françaşois, S., Kraemer, M. U. G.,
550 Faria, N. R., McCrone, J. T., Peng, J., Xiong, Q., Yuan, R., Zeng, L., Zhou, P., Liang, C.,
551 Yi, L., Liu, J., Xiao, J., Hu, J., Liu, T., Ma, W., Li, W., Su, J., Zheng, H., Peng, B., Fang, S.,
552 Su, W., Li, K., Sun, R., Bai, R., Tang, X., Liang, M., Quick, J., Song, T., Rambaut, A.,
553 Loman, N., Raghwanı, J., Pybus, O. G. & Ke, C., 2020. Genomic Epidemiology of SARS-
554 CoV-2 in Guangdong Province, China. *Cell* 181, 997-1003.
- 555 Medema, G., Heijnen, L., Elsinga, G., Italiaander, R. & Brouwer, A., 2020. Presence of SARS-
556 Coronavirus-2 in sewage. *medRxiv preprint*. <https://doi.org/10.1101/2020.03.29.20045880>
- 557 Nemudryi, A., Nemudraia, A., Surya, K., Wiegand, T., Buyukyoruk, M., Wilkinson, R.,
558 Wiedenheft, B., 2020. Temporal detection and phylogenetic assessment of SARS-CoV-2 in
559 municipal wastewater. *medRxiv preprint*. <https://doi.org/10.1101/2020.04.15.20066746>
- 560 Ouali SE, Achkar JP, Lashner B, Regueiro M., 2020. Gastrointestinal manifestations of COVID-19.
561 *Cleveland Clinic Journal of Medicine*. doi:10.3949/ccjm.87a.ccc049
- 562 Park, S. K., Lee, C. W., Park, D. I., Woo, H. Y., Cheong, H. S., Shin, H. C., Ahn, K., Kwon, M. J.,
563 Joo, E. J., 2020. Detection of SARS-CoV-2 in Fecal Samples from Patients with

- 564 Asymptomatic and Mild COVID-19 in Korea. *Clinical Gastroenterology and Hepatology*.
565 <https://doi.org/10.1016/j.cgh.2020.06.005>.
- 566 Peccia, J., Zulli, A., Brackney, D. E., Grubaugh, N. D., Kaplan, E. H., Casanovas-Massana, A.,
567 Ko, A. I., Malik, A. A., Wang, D., Wang, M., Warren, J. L., Weinberger, D. M., Omer, S. B.,
568 2020. SARS-CoV-2 RNA concentrations in primary municipal sewage sludge as a leading
569 indicator of COVID-19 outbreak dynamics. *medRxiv* preprint.
570 <https://doi.org/10.1101/2020.05.19.20105999>
- 571 Protezione Civile, 2020. [https://github.com/pcm-dpc/COVID-19/blob/master/dati-province/dpc-](https://github.com/pcm-dpc/COVID-19/blob/master/dati-province/dpc-covid19-ita-province-20200225.csv)
572 [covid19-ita-province-20200225.csv](https://github.com/pcm-dpc/COVID-19/blob/master/dati-province/dpc-covid19-ita-province-20200225.csv)
- 573 Randazzo, W., Truchado, P., Cuevas-Ferrando, E., Simãñn, P., Allende, A., Sãñnchez, G., 2020.
574 SARS-CoV-2 RNA in wastewater anticipated COVID-19 occurrence in a low prevalence
575 area. *Water Research* 181, 115942.
- 576 Rimoldi, S. G., Stefani, F., Gigantiello, A., Polesello, S., Comandatore, F., Mileto, D., Maresca, M.,
577 Longobardi, C., Mancon, A., Romeri, F., Pagani, C., Moja, L., Gismondo, M. R., Salerno,
578 F., 2020. Presence and vitality of SARS-CoV-2 virus in wastewaters and rivers. *medRxiv*
579 preprint. <https://doi.org/10.1101/2020.05.01.20086009>
- 580 Stefanelli, P., Faggioni, G., Lo, P. A., Fiore, S., Marchi, A., Benedetti, E., Fabiani, C., Anselmo, A.,
581 Ciammaruconi, A., Fortunato, A., De, S. R., Fillo, S., Capobianchi, M. R., Gismondo, M.
582 R., Ciervo, A., Rezza, G., Castrucci, M. R., Lista, F., On Behalf Of Iss Covid-Study Group,
583 2020. Whole genome and phylogenetic analysis of two SARS-CoV-2 strains isolated in Italy
584 in January and February 2020: additional clues on multiple introductions and further
585 circulation in Europe. *Eurosurveillance* 25.
- 586 Tang, A., Tong, Z. D., Wang, H. L., Dai, Y. X., Li, K. F., Liu, J. N., Wu, W. J., Yuan, C., Yu, M.
587 L., Li, P., Yan, J. B., 2020. Detection of Novel Coronavirus by RT-PCR in Stool Specimen
588 from Asymptomatic Child, China. *Emerging Infectious Diseases* 26, 1337-1339.
- 589 Valenti, L., Bergna, A., Pelusi, S., Facciotti, F., Lai, A., Tarkowski, M., Berzuini, A., Caprioli, F.,
590 Santoro, L. Baselli, G., della Ventura, C., Erba, E., Bosari, S., Galli, M., Zehender, G.,
591 Prati, D., 2020. SARS-CoV-2 seroprevalence trends in healthy blood donors during the
592 COVID-19 Milan outbreak. *medRxiv* preprint. <https://doi.org/10.1101/2020.05.11.20098442>
- 593 van Dorp, L., Acman, M., Richard, D., Shaw, L. P., Ford, C. E., Ormond, L., Owen, C. J., Pang, J.,
594 Tan, C. C. S., Boshier, F. A. T., Ortiz, A. T., Balloux, F., 2020. Emergence of genomic
595 diversity and recurrent mutations in SARS-CoV-2. *Infection, Genetics and Evolution* 83,
596 104351.
- 597 Vogels, C.B.F., Brito, A.F., Wyllie, A.L., Fauver, J.R., Ott, I.M., Kalinich, C.C., Petrone, M.E.,
598 Casanovas-Massana, A., Muenker, M.C., Moore, A.J., Klein, J., Lu, P., Lu-Culligan, A.,
599 Jiang, X., Kim, D.J., Kudo, E., Mao, T., Moriyama, M., Eun Oh, J., Park, A., Silva, J., Song,
600 E., Takehashi, T., Taura, M., Tokuyama, M., Venkataraman, A., Weizman, O.-E., Wong, P.,
601 Yang, Y., Cheemarla, N.R., White, E., Lapidus, S., Earnest, R., Geng, B., Vijayakumar, P.,
602 Odio, C., Fournier, J., Bermejo, S., Farhadian, S., Dela Cruz, C., Iwasaki, A., Ko, A.I.,
603 Landry, M.-L., Foxman, E.F., Grubaugh, N.D., 2020. Analytical sensitivity and efficiency
604 comparisons of SARS-COV-2 qRT-PCR primer-probe sets. *medRxiv* preprint.
605 <https://doi.org/10.1101/2020.03.30.20048108>
606

- 607 Volz, E., Baguelin, M. & Bhatia, S. e. al., 2020. Report 5: Phylogenetic analysis of SARS-CoV-2.
608 *Imperial College London*. doi: <https://doi.org/10.25561/77169>.
- 609 Wang, Y., Wang, Y., Chen, Y. & Qin, Q., 2020. Unique epidemiological and clinical features of the
610 emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control
611 measures. *Journal of Medical Virology* 92 (6).
- 612 WHO, 2003. Guidelines for environmental surveillance of poliovirus circulation. Edited by
613 WHO/V&B/03.03.
- 614 WHO, 2020. Coronavirus disease 2019 (COVID-19), Situation Report - 94.
- 615 Wu, F., Xiao, A., Zhang, J., Gu, X., Lee, W. L., Kauffman, K., Hanage, W., Matus, M., Ghaeli, N.,
616 Endo, N., Duvallet, C., Moniz, K., Erickson, T., Chai, P., Thompson, J., Alm, E., 2020.
617 SARS-CoV-2 titers in wastewater are higher than expected from clinically confirmed cases.
618 *medRxiv preprint*. <https://doi.org/10.1101/2020.04.05.20051540>.
- 619 Wurtzer, S., Marechal, V., Mouchel, J. M., Maday, Y., Teyssou, R., Richard, E., Almayrac, J. L.,
620 Moulin, L., 2020. Evaluation of lockdown impact on SARS-CoV-2 dynamics through viral
621 genome quantification in Paris wastewaters. *medRxiv preprint*.
622 <https://doi.org/10.1101/2020.04.12.20062679>.
- 623 Zehender, G., Lai, A., Bergna, A., Meroni, L., Riva, A., Balotta, C., Tarkowski, M., Gabrieli, A.,
624 Bernacchia, D., Rusconi, S., Rizzardini, G., Antinori, S., Galli, M., 2020. Genomic
625 characterization and phylogenetic analysis of SARS-COV-2 in Italy. *Journal of Medical*
626 *Virology*.
- 627 Zhang, Y. Z. & Holmes, E. C., 2020. A Genomic Perspective on the Origin and Emergence of
628 SARS-CoV-2. *Cell* 181, 223-227.
629
630
631

632 **SUPPLEMENTARY MATERIAL**

633 **Table 1: Microorganisms/Nucleic acids tested for evaluation of real-time RT-(q)PCR specificity**

Organism	Strain	Identifier	Notes
Enterovirus 70	J670/71	ATCC 836-VR	
Enterovirus 68	Fermon	ATCC VR-1826	
Coxsackievirus A3	Olson	ATCC 1007-VR	
Coxsackievirus A5	Swartz	ATCC 164-VR	
Coxsackievirus A6	Gdula	ATCC VR-1801	
Coxsackievirus A9	P.B. (Bozek)	ATCC 186-VR	
Echovirus 1	Farouk	ATCC VR-1808	
Echovirus 6	D'Amori	ATCC 36-VR	
Coxsackievirus B6	Schmitt	ATCC 155-VR	
Adenovirus 2	1832	Clinical isolate	
Hepatitis A	HM175	ATCC 2089-VR	
Hepatitis E	47832c	///	Kindly provided by Dr. Reimar Johne (Bundesinstitut für Risikobewertung)
Rotavirus group A	G9P[9]	///	Kindly provided by Dr. Roberto Delogu (Istituto Superiore di Sanità)
NoV Reference Panel *	GI.1	///	Provided by Rijksinstituut voor Volksgezondheid en Milieu (RIVM, The Netherland)
NoV Reference Panel *	GI.2 Whiterose	///	“
NoV Reference Panel *	GI.2 Southampton	///	“
NoV Reference Panel *	GI.3	///	“
NoV Reference Panel *	GI.4	///	“
NoV Reference Panel *	GI.5	///	“
NoV Reference Panel *	GI.6	///	“
NoV Reference Panel *	GI.7	///	“
NoV Reference Panel *	GI.10	///	“
NoV Reference Panel *	GII.1	///	“
NoV Reference Panel *	GII.2	///	“
NoV Reference Panel *	GII.3	///	“
NoV Reference Panel *	GII.4	///	“
NoV Reference Panel *	GII.6	///	“
NoV Reference Panel *	GII.7	///	“
NoV Reference Panel *	GII.10	///	“
NoV Reference Panel *	GII.b	///	“
NoV Reference Panel *	GII.c	///	“
NoV Reference Panel *	GIV Alphanon	///	“
<i>Bacillus cereus</i>		ATCC 11778	
<i>Bacillus licheniformis</i>		Environmental isolate	
<i>Bacillus subtilis</i>		ATCC 6633	
<i>Enterobacter aerogenes</i>		ATCC 13048	
<i>Enterococcus faecalis</i>		ATCC 29212	
<i>Escherichia coli</i>		ATCC 25922	
<i>Listeria innocua</i>		ATCC 33090	
<i>Proteus hauseri</i>		ATCC 13315	
<i>Pseudomonas aeruginosa</i>		ATCC 9027	
<i>Rhodococcus equi</i>		ATCC 6939	
<i>Salmonella enteritidis</i>		ATCC 13076	

<i>Salmonella typhimurium</i>		ATCC 14028	
<i>Shigella sonnei</i>		ATCC 25931	
<i>Staphylococcus aureus</i>		ATCC 25923	
<i>Staphylococcus epidermidis</i>		ATCC 12228	

634

635

636

637

638

* The NoV Reference panel includes in vitro synthesized RNA from region A, B and C of NoV genomes ("Development and application of a capsid VP1 (region D) based reverse transcription PCR assay for genotyping of genogroup I and II noroviruses" - Jan Vinjé, Raditijo A Hamidjaja, Mark Sobsey, Journal of Virological Methods, 2004; 116(2):109-17)